Bayer AG ((BAYRY)), Bayer Ag (UK) ((GB:0P6S)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Bayer AG has recently completed a clinical study titled A Prospective, Interventional, Multicenter, Phase IV, Open-label, Single Arm Study to Assess the Safety and Effectiveness of Finerenone in Participants From India With Chronic Kidney Disease Associated With Type 2 Diabetes. The study aimed to evaluate the safety and effectiveness of Finerenone, a drug already approved in India, for treating chronic kidney disease (CKD) in patients with type 2 diabetes (T2D). This study is significant as it seeks to provide insights into the drug’s performance specifically in the Indian population.
The intervention tested in this study is Finerenone, marketed under the name Kerendia (BAY94-8862). It is a film-coated tablet taken orally once daily, designed to block mineralocorticoid receptors, which are believed to contribute to kidney injury and inflammation in CKD patients.
This Phase IV study employed an interventional, single-group design with no masking, focusing on treatment as its primary purpose. Participants took Finerenone for 18 months, with regular monitoring of their health and kidney function.
The study began on February 8, 2023, and was completed on July 8, 2025. These dates are crucial as they mark the timeline for data collection and analysis, providing a basis for future regulatory and clinical decisions.
From a market perspective, the successful completion of this study could positively impact Bayer AG’s stock performance by reinforcing investor confidence in Finerenone’s market potential in India. It also positions Bayer favorably against competitors in the CKD treatment space, potentially leading to increased market share.
The study is now completed, and further details are available on the ClinicalTrials portal.